Search Within

Department of Medicine

Formats
  1. Journal Article (19593)
  2. Meeting Abstract (16038)
  3. Review (1150)
  4. Book Section (934)
  5. Editorial (610)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22321)
  2. Hematologic Malignancies, Division of (13278)
  3. Center for Hematologic Malignancies (11061)
  4. GSK Faculty (10646)
  5. Survivorship Research (9330)
  6. Division of Subspecialty Medicine (7535)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1071)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2111)

More Publishers

Results (39622)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors
    Meeting Abstract

    Schoenfeld, A. J.; Warner, A. B.; Chesney, J. A.; Thomas, S. S.; Hamid, O.; In, G. K.; Shoushtari, A. N.; Samhouri, Y.; Hari, P. N.; Ramsingh, G.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Karimi, Y.; Abrisqueta, P.; de Vos, S.; Nijland, M.; Offner, F.; Osei-Bonsu, K.; Rana, A.; Archer, K. G.; Song, Y.; Cordoba, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naive myelofibrosis
    Meeting Abstract

    Mascarenhas, J.; Maher, K. R.; Rampal, R.; Bose, P.; Podoltsev, N. A.; Hong, J.; Wang, X.; Kye, S.; Harrison, C.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune)
    Meeting Abstract

    McKay, R. R.; Liu, L.; Pu, M.; Araneta, A.; Yuen, K. L.; Gomez, J.; Castano, N.; Ajmera, A.; Ye, H.; Pili, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Patient characteristics associated with primary prophylactic granulocyte colony-stimulating factor (G-CSF) use among women treated for early-stage breast cancer
    Meeting Abstract

    Gallagher, G. B.; O'Connell, K.; Bhimani, J.; Blinder, V. S.; Burganowski, R. P.; Griggs, J. J.; Kolevska, T.; Kroenke, C.; Laurent, C.; Liu, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors
    Meeting Abstract

    Raufi, A. G.; Goyal, L.; Smyth, E.; Szekeres, P.; Petrone, M.; Hobson, R.; Thress, K.; Origuchi, M.; Nehra, J.; Brown, J. S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • AMPLIFY-7P, a first-in-human safety and efficacy trial of adjuvant mKRAS-specific lymph node targeted amphiphile ELI-002 7P vaccine in patients with minimal residual disease-positive pancreatic and colorectal cancer
    Meeting Abstract

    Devoe, C. E.; Pant, S.; Wainberg, Z. A.; Chung, V.; George, T. J.; Kasi, P. M.; VanWyk, H.; Tavares, A.; Perry, J.; Kheoh, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Safety outcomes in patients with acute myeloid leukemia receiving gemtuzumab ozogamicin and proceeding to allogeneic hematopoietic stem cell transplantation
    Meeting Abstract

    Kebriaei, P.; Ho, V.; Perales, M. A.; Bejanyan, N.; Kaur, M.; Zhang, M. J.; D'Amico, P. G.; Purcell, S.; Dorman, S.; Vandendries, E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b/2 study (RAMP 205)
    Meeting Abstract

    Lim, K. H.; Spencer, K. R.; Safyan, R. A.; Picozzi, V. J.; Varghese, A. M.; Siolas, D.; Perez, K.; Clift, S.; Denis, L. J.; Bhambhani, V.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results
    Meeting Abstract

    Segal, N. H.; Girda, E.; Sohal, D.; Lakhani, N. J.; Olszanski, A. J.; Fong, L.; Kinnaman, M. D.; Han, H.; Skokos, D.; Casey, K. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save